June 4 (Reuters) - Cullinan Therapeutics Inc CGEM.O:
CULLINAN THERAPEUTICS LICENSES RIGHTS TO VELINOTAMIG, A CLINICAL-STAGE BCMA-DIRECTED BISPECIFIC T CELL ENGAGER, FROM GENRIX BIO FOR DEVELOPMENT IN AUTOIMMUNE DISEASES
CULLINAN THERAPEUTICS INC - TO PAY $20 MILLION UPFRONT LICENSE FEE TO GENRIX BIO
CULLINAN THERAPEUTICS INC - GENRIX ELIGIBLE FOR UP TO $292 MILLION IN MILESTONES
CULLINAN THERAPEUTICS INC - EXPECTS CASH RESOURCES TO LAST INTO 2028
CULLINAN THERAPEUTICS : GENRIX TO RECEIVE UP TO AN ADDITIONAL $400M IN SALES-BASED MILESTONES
Source text: ID:nGNXc1sZxw
Further company coverage: CGEM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.